Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Nanobiotix ADR Representing Ord Shs NBTX

Healthcare Biotechnology
Nanobiotix SA is a France-based nanomedicine company. The Company designs and manufactures nanoparticles that safely enhance the efficacy of radiation therapy in the treatment of cancer. It develops new tools for cancer that utilize a physical mode of action at the cellular level of the cancer cell. The Company's NanoXray technology comprises three products. Local treatment (surgery and radiotherapy) provides potential cure and gives the systemic treatment a better chance to life expectancy. NanoXray products are developed for the efficacy of radiotherapy in the tumor cell. Nanobiotix is a spin-off of the State University of New York (SUNY) at Buffalo.


NDAQ:NBTX - Post by User

Nanobiotix ADR Representing Ord Shs
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(166)
•••
Post by whytestockson May 28, 2024 8:45pm
46 Views
Post# 36061476

NANOBIOTIX Announces Presentation of new Data From Phase 1 I

NANOBIOTIX Announces Presentation of new Data From Phase 1 I
JUST IN: $NBTX NANOBIOTIX Announces Presentation of new Data From Phase 1 Immunotherapy Program at the 2024 Annual Meeting of the American Society for Clinical Oncology Followed by an Investor Conference Call | BenzingaNew data from the completed dose escalation part and ongoing expansion part of Study 1100, an ongoing US Phase 1 study evaluating NBTXR3 followed...NBTX - NANOBIOTIX Announces Presentation of new Data From Phase 1 Immunotherapy Program at the 2024 Annual Meeting of the American Society for Clinical Oncology Followed by an Investor Conference Call | Benzinga


<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities